THE SAFETY AND OUTCOME OF ACUTE ISCHAEMIC STROKE PATIENTS WITH COVID-19 TREATED WITH INTRAVENOUS RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.21776/ub.mnj.2024.010.02.12Keywords:
Acute Ischemic Stroke, Covid-19, National Institutes of Health Stroke Scale (NIHSS), IV Thrombolytic, Outcome, safetyAbstract
Background: Strokes associated with SARS-CoV-2 may be linked to increased mortality rates. The utilization of intravenous thrombolysis is anticipated to enhance the clinical results in such patients. Moreover, emerging evidence underscores the importance of evaluating the safety and effectiveness of intravenous thrombolysis in individuals suffering from Acute Ischaemic Stroke along with COVID-19.
Objective: To assess the safety and effectiveness of intravenous thrombolysis in Acute Ischaemic Stroke patients with COVID-19.
Methods: A systematic literature search (Pubmed, Elsevier, and Cochrane database) with keywords (((intravenous thrombolysis) AND (acute ischemic stroke)) AND (covid-19)) AND (outcome))). We selected research studies for evaluation based on specific inclusion and eligibility criteria. Two independent reviewers then proceeded to extract and analyze various data points, including the name of the first author, the year of publication, the study's design, the National Institute of Health Stroke Scale (NIHSS) scores at admission and post-treatment, hospitalization-related mortality, and the occurrence of hemorrhagic transformation.
Results: Three studies (n=153 patients) were included, mostly men with advanced age with the most common comorbidity being hypertension. Median of NIHSS Score of subjects on admission is 11, 12, and 13, with interquartile range from 3 to 20 (minor to severe stroke). The mRS at discharge and 1 month after admission is: 0–2 pts in 57 patients, ≥2 in 43 patient. Hemorrhagic transformation involved 3.23% of patients from total samples, death within hospitalization and 1-month mortality were in 23 patients (15%). In numerous studies, there was inadequate data available to determine the precise reason for mortality.
Conclusion: Following IV-rTPA therapy, our COVID-19 infection subjects' mRS scores ranged from mild to moderate disability. Fifteen percents of all subjects died, and 3.23% of subjects experienced hemorrhagic transformation. However, majority of our subjects have high median NIHSS scores at admission, advanced age, complicated with baseline risk factors as high blood pressure, diabetes, and hyperlipidemia.
Downloads
References
Fifi JT, Mocco J. COVID-19 related stroke in young individuals. Lancet Neurol; 2020. Sep;19(9):713–5. DOI: 10.1016/S1474-4422(20)30272-6
Bialek S, Boundy E, Bowen V, Chow N, Cohn A, Dowling N, et al. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) — United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep; 2020. Mar 27;69(12):343–6. DOI: 10.15585/mmwr.mm6912e2
Martí-Fàbregas J, Guisado-Alonso D, Delgado-Mederos R, Martínez-Domeño A, Prats-Sánchez L, Guasch-Jiménez M, et al. Impact of COVID-19 infection on the outcome of patients with ischemic stroke. Stroke; 2021. Dec;52(12):3908–17.
Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Chest; 1992. Mar;101(3):816–23. DOI: 10.1378/chest.101.3.816
Zhang S, Zhang J, Wang C, Chen X, Zhao X, Jing H, et al. COVID 19 and ischemic stroke: Mechanisms of hypercoagulability (Review). Int J Mol Med; 2021. Jan 13;47(3):21. DOI: 10.3892/ijmm.2021.4854
Hudock KM, Collins MS, Imbrogno M, Snowball J, Kramer EL, Brewington JJ, et al. Neutrophil extracellular traps activate IL-8 and IL-1 expression in human bronchial epithelia. Am J Physiol Cell Mol Physiol; 2020. Jul 1;319(1):L137–47.
Mac Grory B, Saldanha IJ, Mistry EA, Stretz C, Poli S, Sykora M, et al. Thrombolytic therapy for wake‐up stroke: A systematic review and meta‐analysis. Eur J Neurol; 2021. Jun 15;28(6):2006–16.
Gelener P, Halil Akpinar S. Recent advances in thrombolysis and thrombectomy in acute ischemic stroke treatment: Neurologist’s and interventional neuroradiologist’s perspective. In: Thrombectomy - Recent advances in ischaemic damage treatment [Working Title]. IntechOpen; 2021. DOI: 10.5772/intechopen.100502
Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management. Thromb Res; 2020. Oct;194:101–15. DOI: 10.1016/j.thromres.2020.06.029
Sobolewski P, Antecki J, Brola W, Fudala M, Bieniaszewski L, Kozera G. Systemic thrombolysis in ischaemic stroke patients with COVID‐19. Acta Neurol Scand; 2022. Jan 20;145(1):47–52.
Cappellari M, Zini A, Sangalli D, Cavallini A, Reggiani M, Sepe FN, et al. Thrombolysis and bridging therapy in patients with acute ischaemic stroke and Covid‐19. Eur J Neurol; 2020. Dec 15;27(12):2641–5. DOI: 10.1111/ene.14511
Sasanejad P, Afshar Hezarkhani L, Arsang-Jang S, Tsivgoulis G, Ghoreishi A, Barlinn K, et al. Safety and Outcomes of Intravenous Thrombolytic Therapy in Ischemic Stroke Patients with COVID-19: CASCADE Initiative. J Stroke Cerebrovasc Dis; 2021. Dec;30(12):106121. DOI: 10.1016/j.jstrokecerebrovasdis.2021.106121
Desilles J, Syvannarath V, Di Meglio L, Ducroux C, Boisseau W, Louedec L, et al. Downstream microvascular thrombosis in cortical venules is an early response to proximal cerebral arterial occlusion. J Am Heart Assoc; 2018. Mar 6;7(5).
Akhtar N, Abid F Ben, Kamran S, Singh R, Imam Y, AlJerdi S, et al. Characteristics and comparison of 32 COVID-19 and non-COVID-19 ischemic strokes and historical stroke patients. J Stroke Cerebrovasc Dis; 2021. Jan;30(1):105435.
Di Meglio L, Desilles J-P, Ollivier V, Nomenjanahary MS, Di Meglio S, Deschildre C, et al. Acute ischemic stroke thrombi have an outer shell that impairs fibrinolysis. Neurology; 2019. Oct 29;93(18):e1686–98. DOI: 10.1212/WNL.0000000000008395
Staessens S, Denorme F, Francois O, Desender L, Dewaele T, Vanacker P, et al. Structural analysis of ischemic stroke thrombi: Histological indications for therapy resistance. Haematol; 2020. Feb;105(2):498–507. DOI: 10.3324/haematol.2019.219881
Genchi A, Semerano A, Schwarz G, Dell’Acqua B, Gullotta GS, Sampaolo M, et al. Neutrophils predominate the immune signature of cerebral thrombi in COVID-19 stroke patients. Acta Neuropathol Commun; 2022. Dec 1;10(1):14.
Conti P, Younes A. Coronavirus COV-19/SARS-CoV-2 affects women less than men: Clinical response to viral infection. J Biol Regul Homeost Agents; 2020. 34(2):339–43. DOI:10.23812/editorial-conti-3
Reeves MJ, Bushnell CD, Howard G, Gargano JW, Duncan PW, Lynch G, et al. Sex differences in stroke: Epidemiology, clinical presentation, medical care, and outcomes. Lancet Neurol; 2008. Oct;7(10):915–26.
Bwire GM. Coronavirus: Why men are more vulnerable to covid-19 than women? SN Compr Clin Med; 2020. Jul 4;2(7):874–6. DOI: 10.1007/s42399-020-00341-w
Meseguer E, Mazighi M, Labreuche J, Arnaiz C, Cabrejo L, Slaoui T, et al. Outcomes of intravenous recombinant tissue plasminogen activator therapy according to gender. Stroke; 2009 Jun;40(6):2104–10.
Roy-O'Reilly M, McCullough LD. Age and sex are critical factors in ischemic stroke pathology. Endocrinology; 2018. Aug 1;159(8):3120-3131. DOI: 10.1210/en.2018-00465.
Tascioglu D, Yalta K, Yetkin E. Hypertension and diabetes mellitus in patients with COVID-19: A viewpoint on mortality. Cardiovasc Endocrinol Metab; 2020. Jun 2;9(3):108–9.
Urbach H, Hartmann A, Pohl C, Omran H, Wilhelm K, Flacke S, et al. Local intra-arterial thrombolysis in the carotid territory: Does recanalization depend on the thromboembolus type? Neuroradiology; 2002. Aug 18;44(8):695–9. DOI: 10.1007/s00234-002-0762-6
Jiang Y, Han J, Spencer P, Li Y, Vodovoz SJ, Ning M-M, et al. Diabetes mellitus: A common comorbidity increasing hemorrhagic transformation after tPA thrombolytic therapy for ischemic stroke. Brain Hemorrhages; 2021. Sep;2(3):116–23.
Nicolai L, Leunig A, Brambs S, Kaiser R, Weinberger T, Weigand M, et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation; 2020. Sep 22;142(12):1176–89.
DOI: 10.1161/CIRCULATIONAHA.120.048488
Zaid Y, Puhm F, Allaeys I, Naya A, Oudghiri M, Khalki L, et al. Platelets can associate with SARS CoV-2 RNA and are hyperactivated in COVID-19. Circ Res; 2020. Nov 6;127(11):1404–18. DOI: 10.1161/CIRCRESAHA.120.317703
Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, et al. Platelet gene expression and function in patients with COVID-19. Blood; 2020. Sep 10;136(11):1317–29.
Mathew T, John SK, Sarma G, Nadig R, Kumar R S, Murgod U, et al. COVID-19-related strokes are associated with increased mortality and morbidity: A multicenter comparative study from Bengaluru, South India. Int J Stroke; 2021. Jun 6;16(4):429–36. DOI: 10.1177/1747493020968236
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 MNJ (Malang Neurology Journal)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
